Bristol-Myers Sues MSN to Block Copies of Blockbuster Pomalyst

Bristol-Myers Squibb Co.’s Celgene Corp. filed a lawsuit Wednesday alleging that generic versions of Pomalyst proposed by MSN Laboratories Private Ltd. infringe six patents related to the blockbuster cancer drug, whose U.S. sales accounted for nearly 5% of Bristol-Myers’ 2021 revenue.

Pomalyst and some of the same patents were part of 25 federal lawsuits, all in New Jersey, that Celgene later settled. The most recent pact came in January, when Celgene confidentially settled the last of several cases over Dr. Reddy’s Laboratories Ltd.’s proposed copycat.

MSN wants to sell cheaper versions of Pomalyst’s 2-, 3-, and 4-milligram capsules, according ...